US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CytoDyn Inc.

0.2586

-0.0074-2.78%

Volume:3.63M

Turnover:954.53K

Market Cap:324.19M

PE:-7.98

High:0.2708

Open:0.2700

Low:0.2537

Close:0.2660

52wk High:0.4470

52wk Low:0.1925

Shares:1.25B

Float Shares:1.25B

Volume Ratio:1.67

T/O Rate:0.29%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0324

EPS(LYR):-0.2868

ROE:1659.17%

ROA:-70.67%

PB:-2.71

PE(LYR):-0.90

Loading ...

Overview Company News Filings

CytoDyn Reports New Leronlimab Survival and Mechanism Data in Metastatic Triple-Negative Breast Cancer at AACR IO

CytoDyn announces benefactor committed funding to support EAP

Cytodyn Announces Funding and Initiation of Expanded Access Program for Patients With Triple-Negative Breast Cancer

THOMSON REUTERS

CytoDyn Inc. reports Q2 net loss of USD 22.6 million, widening nearly 5 times

CytoDyn Reports Leronlimab Boosts PD-L1 and Extends Survival in Metastatic Triple-Negative Breast Cancer

CytoDyn Reaches Settlement in Securities Class Action Lawsuit

CytoDyn Reports Prolonged Survival With Leronlimab in Metastatic Triple-Negative Breast Cancer

BRIEF-CytoDyn Inc Files For Offering Of Up To 120 Million Shares Of Common Stock By Selling Stockholder - SEC Filing

Cytodyn Inc Files for Offering of up to 120 Mln Shares of Common Stock by Selling Stockholder - SEC Filing

THOMSON REUTERS

CytoDyn Secures $30 Million Equity Commitment from Yorkville Advisors

CytoDyn Inc to Present at LD Micro Main Event XIX Investor Conference

CytoDyn Inc. Announces New Clinical Data: Leronlimab Shows Enhanced PD-L1 Expression and Improved Survival in Metastatic Triple-Negative Breast Cancer

CytoDyn Inc. Announces Date for 2025 Annual Meeting of Stockholders

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CYDY/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CYDY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CYDY\",,,,,undefined,":{"symbol":"CYDY","market":"US","secType":"STK","nameCN":"CytoDyn Inc.","latestPrice":0.2586,"timestamp":1771966778218,"preClose":0.266,"halted":0,"volume":3631197,"delay":15,"changeRate":-0.027819548872180515,"floatShares":1252865057,"shares":1253645452,"eps":-0.032401,"marketStatus":"Post-Mkt","change":-0.0074,"latestTime":"02-24 15:59:38 EST Delay","open":0.27,"high":0.2708,"low":0.2537,"amount":954529.048429,"amplitude":0.064286,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.032401,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1771981200000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"OTCQB","adjPreClose":0.266,"volumeRatio":1.668959},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CYDY\",,,,,undefined,":{"symbol":"CYDY","floatShares":1252865057,"roa":"-70.67%","roe":"1659.17%","lyrEps":-0.286757,"volumeRatio":1.668959,"shares":1253645452,"dividePrice":0,"high":0.2708,"amplitude":0.064286,"preClose":0.266,"low":0.2537,"week52Low":0.1925,"pbRate":"-2.71","week52High":0.447,"institutionHeld":0,"latestPrice":0.2586,"eps":-0.032401,"divideRate":0,"volume":3631197,"delay":15,"ttmEps":-0.032401,"open":0.27,"prevYearClose":0.28,"prevWeekClose":0.2593,"prevMonthClose":0.2444,"prevQuarterClose":0.28,"fiveDayClose":0.243,"twentyDayClose":0.2511,"sixtyDayClose":0.345},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CYDY\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-01-14","symbol":"CYDY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1736830800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-10-15","symbol":"CYDY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1728964800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-08-15","symbol":"CYDY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723694400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-04-15","symbol":"CYDY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1713153600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-01-16","symbol":"CYDY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1705381200000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CYDY\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CYDY\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CYDY\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2612759262","title":"CytoDyn Reports New Leronlimab Survival and Mechanism Data in Metastatic Triple-Negative Breast Cancer at AACR IO","url":"https://stock-news.laohu8.com/highlight/detail?id=2612759262","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612759262?lang=en_us&edition=fundamental","pubTime":"2026-02-20 21:30","pubTimestamp":1771594216,"startTime":"0","endTime":"0","summary":"CytoDyn Inc. announced new preclinical, translational, and retrospective clinical findings supporting its CCR5-targeting monoclonal antibody leronlimab in metastatic triple-negative breast cancer , including a pooled analysis of 28 heavily pretreated patients from three trials and mechanistic data on T-cell exhaustion pathways and PD-L1/PD1 biology. The company said the data were presented at the AACR Immuno-Oncology Conference held February 18–21, 2026, including a poster presentation on February 19, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoDyn Inc. published the original content used to generate this news brief via GlobeNewswire  on February 20, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nNDL10hNxH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","SG9999014013.SGD","LU2095319765.USD","BK4585","BK4112","CYDY","BK4588","LU2210150020.SGD","SG9999014005.SGD","BK4139","IE00BKPKM429.USD","LU2210149790.SGD","NDAQ","SG9999014021.USD","SG9999014039.USD"],"gpt_icon":0},{"id":"2606787363","title":"CytoDyn announces benefactor committed funding to support EAP","url":"https://stock-news.laohu8.com/highlight/detail?id=2606787363","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606787363?lang=en_us&edition=fundamental","pubTime":"2026-01-27 21:40","pubTimestamp":1769521219,"startTime":"0","endTime":"0","summary":"CytoDyn (CYDY) announced that a benefactor has formally committed funding to support the Company’s Expanded Access Program, EAP, for patients with ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cytodyn-announces-benefactor-committed-funding-to-support-eap-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cytodyn-announces-benefactor-committed-funding-to-support-eap-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CYDY"],"gpt_icon":0},{"id":"2606782120","title":"Cytodyn Announces Funding and Initiation of Expanded Access Program for Patients With Triple-Negative Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2606782120","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606782120?lang=en_us&edition=fundamental","pubTime":"2026-01-27 21:30","pubTimestamp":1769520602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nTUABCMRNN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CYDY"],"gpt_icon":0},{"id":"2602379881","title":"CytoDyn Inc. reports Q2 net loss of USD 22.6 million, widening nearly 5 times","url":"https://stock-news.laohu8.com/highlight/detail?id=2602379881","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602379881?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:31","pubTimestamp":1767965496,"startTime":"0","endTime":"0","summary":"CytoDyn Inc. reported a net loss of USD 22.6 million for the quarter ending November 30, 2025. Total interest and other expenses for the quarter amounted to USD 919 thousand. No income tax benefit was recognized during the period. Loss per share data was not disclosed in the provided information.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoDyn Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 09, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL4HswCQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CYDY"],"gpt_icon":0},{"id":"2589355624","title":"CytoDyn Reports Leronlimab Boosts PD-L1 and Extends Survival in Metastatic Triple-Negative Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2589355624","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589355624?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:30","pubTimestamp":1765200658,"startTime":"0","endTime":"0","summary":"CytoDyn Inc., a clinical-stage oncology company, announced updated results from a retrospective follow-up analysis involving 28 women with metastatic triple-negative breast cancer  who participated in three leronlimab clinical trials. The findings, which will be presented as a poster at the San Antonio Breast Cancer Symposium on December 12, 2025, indicate that leronlimab treatment is associated with upregulation of PD-L1 in circulating tumor cells and cancer-associated macrophage-like cells. Among patients who demonstrated significant PD-L1 induction and subsequently received immune checkpoint inhibitors, all remain alive after a median of 60.9 months, with three showing no evidence of disease. No dose-limiting toxicities were observed, and no patients withdrew due to treatment-related adverse events. A copy of the presentation will be made available on CytoDyn's website after the symposium.Disclaimer: This news brief was created by Public Technologies  using generative artificial int","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL7VrqfZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4139","IE00BKPKM429.USD","SG9999014005.SGD","LU0314104364.USD","IE00B3QW5Z07.USD","LU2095319765.USD","LU2210150020.SGD","NDAQ","SG9999014039.USD","CYDY","BK4585","SG9999014021.USD","LU2210149790.SGD","BK4112","SG9999014013.SGD","BK4588"],"gpt_icon":0},{"id":"2588786557","title":"CytoDyn Reaches Settlement in Securities Class Action Lawsuit","url":"https://stock-news.laohu8.com/highlight/detail?id=2588786557","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588786557?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:30","pubTimestamp":1764595811,"startTime":"0","endTime":"0","summary":"CytoDyn Inc. has reached an agreement in principle to resolve a securities class action lawsuit that was initially filed in March 2021 against the company and certain former officers. The case, pending in the United States District Court for the Western District of Washington and titled Courter et al. v. CytoDyn Inc. et al., is subject to final court approval. The settlement is expected to provide clarity and finality for the company and its stakeholders. CytoDyn stated that resolving the litigation allows the company to focus on advancing its clinical development programs, including new Phase II studies for leronlimab in metastatic colorectal cancer and metastatic triple-negative breast cancer. Additional information has been included in the company's filings with the Securities and Exchange Commission.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL65ywfw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","IE00BKPKM429.USD","LU2095319765.USD","IE00B64PRP62.GBP","BK4139","LU2210149790.SGD","NDAQ","BK4112","BK4585","LU2210150020.SGD","CYDY","LU0314104364.USD"],"gpt_icon":0},{"id":"2585566467","title":"CytoDyn Reports Prolonged Survival With Leronlimab in Metastatic Triple-Negative Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2585566467","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585566467?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:30","pubTimestamp":1763991025,"startTime":"0","endTime":"0","summary":"CytoDyn Inc. has announced that it will present new clinical data on leronlimab in patients with metastatic or locally advanced triple-negative breast cancer at the upcoming San Antonio Breast Cancer Symposium, taking place December 9-12, 2025. The presentation, led by Dr. Milana V. Dolezal from Stanford University School of Medicine, will focus on prolonged survival following immune checkpoint inhibitor therapy with or after leronlimab treatment. According to the company, the data suggest that leronlimab may increase PD-L1 levels, potentially improving the efficacy of immune checkpoint inhibitors in this patient population. The poster will be available on December 12, 2025, and materials will be posted to CytoDyn's website following the presentation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and shoul","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL3tZGVM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYDY","IE00BKPKM429.USD","BK4112","IE00B64PRP62.GBP","LU2210149790.SGD","BK4139","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","BK4585","LU2210150020.SGD","NDAQ","LU2095319765.USD","BK4588"],"gpt_icon":0},{"id":"2581179808","title":"BRIEF-CytoDyn Inc Files For Offering Of Up To 120 Million Shares Of Common Stock By Selling Stockholder - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2581179808","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581179808?lang=en_us&edition=fundamental","pubTime":"2025-11-05 06:30","pubTimestamp":1762295403,"startTime":"0","endTime":"0","summary":"BRIEF-CytoDyn Inc Files For Offering Of Up To 120 Million Shares Of Common Stock By Selling Stockholder - SEC FilingNov 4  - Cytodyn Inc CYDY.PK:CYTODYN INC FILES FOR OFFERING OF UP TO 120 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDER - SEC FILINGSource text: [ID:n0001104659-25-106415]Further company coverage: CYDY.PK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nFWN3WG188:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYDY","BK4139"],"gpt_icon":0},{"id":"2581798373","title":"Cytodyn Inc Files for Offering of up to 120 Mln Shares of Common Stock by Selling Stockholder - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2581798373","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581798373?lang=en_us&edition=fundamental","pubTime":"2025-11-05 06:17","pubTimestamp":1762294624,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nFWN3WG188:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CYDY","BK4139"],"gpt_icon":0},{"id":"2580215271","title":"CytoDyn Secures $30 Million Equity Commitment from Yorkville Advisors","url":"https://stock-news.laohu8.com/highlight/detail?id=2580215271","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580215271?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:30","pubTimestamp":1762176639,"startTime":"0","endTime":"0","summary":"CytoDyn Inc. announced it has secured a $30 million funding commitment from Yorkville Advisors Global. Under the terms of the agreement, CytoDyn has the right to sell, and Yorkville is obligated to purchase, up to $30 million of CytoDyn's common stock over the next 36 months. The company will control the timing of all sales at its sole discretion, with no minimum commitments, penalties, or share classes such as warrants or derivatives involved. CytoDyn is not required to utilize the full amount and the arrangement imposes no restrictions on its operations. The proceeds are intended to support the further development of CytoDyn's leronlimab program.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoDyn Inc. published the original conte","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL9mcpDW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","LU2095319765.USD","IE00BKPKM429.USD","CYDY","IE00B3QW5Z07.USD","LU2210150020.SGD","NDAQ","IE00B64PRP62.GBP","BK4112","IE00BGHQF748.EUR","LU2210149790.SGD","LU0314104364.USD","BK4585"],"gpt_icon":0},{"id":"2574152799","title":"CytoDyn Inc to Present at LD Micro Main Event XIX Investor Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2574152799","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574152799?lang=en_us&edition=fundamental","pubTime":"2025-10-09 20:30","pubTimestamp":1760013020,"startTime":"0","endTime":"0","summary":"CytoDyn Inc., a clinical-stage oncology company developing leronlimab for multiple cancer indications, will present a corporate overview at the LD Micro Main Event XIX Investor Conference on October 21, 2025. CFO Robert E. Hoffman is scheduled to deliver the presentation at 9 a.m. PDT.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoDyn Inc. published the original content used to generate this news brief via GlobeNewswire  on October 09, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251009:nNDL8TXh5J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4112","LU0314104364.USD","LU2210149790.SGD","IE00B64PRP62.GBP","CYDY","BK4585","LU2210150020.SGD","NDAQ","BK4588","IE00B3QW5Z07.USD","LU2095319765.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2570018471","title":"CytoDyn Inc. Announces New Clinical Data: Leronlimab Shows Enhanced PD-L1 Expression and Improved Survival in Metastatic Triple-Negative Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2570018471","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570018471?lang=en_us&edition=fundamental","pubTime":"2025-09-25 21:21","pubTimestamp":1758806470,"startTime":"0","endTime":"0","summary":"CytoDyn Inc. Announces New Clinical Data: Leronlimab Shows Enhanced PD-L1 Expression and Improved Survival in Metastatic Triple-Negative Breast Cancer. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoDyn Inc. published the original content used to generate this news brief via GlobeNewswire  on September 25, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250925:nNDL17tXHr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4139","BK4112","IE00BGHQF748.EUR","NDAQ","BK4585","LU2210150020.SGD","BK4588","LU2210149790.SGD","LU0314104364.USD","CYDY","IE00B3QW5Z07.USD","LU2095319765.USD"],"gpt_icon":0},{"id":"2569172717","title":"CytoDyn Inc. Announces Date for 2025 Annual Meeting of Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2569172717","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569172717?lang=en_us&edition=fundamental","pubTime":"2025-09-24 01:32","pubTimestamp":1758648732,"startTime":"0","endTime":"0","summary":"CytoDyn Inc. is set to hold its 2025 Annual Meeting of Stockholders online via a live webcast on November 21, 2025. The meeting will provide stockholders the opportunity to discuss various matters pertinent to the company's operations and governance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoDyn Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 19, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nNDL6KdhBD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYDY","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":13,"code":"91000000","status":"200"}]}}